RxDoctor Payments DataLook up a doctor →

Celina Hamdan, PA

Physician Assistant · Alcoa, TNNPI 1285224899

Payments from drug & device makers

$24,288in general payments, 2019–2025

Across 504 payments — averaging $48.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$8K
  • Pfizer$4K
  • Livanova USA, Inc.$3K
  • UCB, Inc.$2K
  • CSL Behring$495
  • Neurocrine Biosciences, Inc.$468
  • plus $6K from 46 others

What the payments were for

  • Consulting fees$6753%
  • Speaking & faculty fees$9,46339%
  • Travel & lodging$2,58811%
  • Food & beverage$11,55948%
  • Education$40%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,288 in reported general payments places this provider in the 95th percentile of 2,404 physician assistant providers in Tennessee.

See all physician assistant providers in Tennessee

Medicare billing

Part B allowed, 2024
$67,814
Medicare patients
320
Services billed
2,716

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BriviactBrivaracetam74$123,192
Nurtec OdtRimegepant Sulfate94$120,448
FycompaPerampanel93$117,911
BetaseronInterferon Beta-1b11$105,787
AustedoDeutetrabenazine11$95,059
Aimovig AutoinjectorErenumab-Aooe100$85,169
QuliptaAtogepant58$83,992
Teriflunomide12$52,654
Emgality PenGalcanezumab-Gnlm61$43,958
AptiomEslicarbazepine Acetate20$42,530
UbrelvyUbrogepant28$34,071
BotoxOnabotulinumtoxina23$29,152
XcopriCenobamate23$28,803
NeuproRotigotine20$26,776
VimpatLacosamide16$25,308

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact, Neupro, Vimpat$1,598$175,276110 claims
AbbVieQulipta, Ubrelvy, Botox$8,127$147,215109 claims
PfizerNurtec Odt, Dilantin$4,195$130,544136 claims
Eisai Inc.Fycompa$356$117,91193 claims
Teva Pharmaceuticals USA, Inc.Austedo$291$95,05911 claims
SK Life Science, Inc.Xcopri$200$28,80323 claims
Avanir Pharmaceuticals, Inc.Nuedexta$138$23,17815 claims
Supernus Pharmaceuticals, Inc.Oxtellar Xr$107$22,75312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,404 physician assistant providers in Tennessee.

Other physician assistant in Alcoa

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →